Prosecution Insights
Prosecution Insights
12 pending office actions • 6 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (8%) |
| §112 only | 2 (17%) |
| No statute on record | 9 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHASE, CAROL ANN | 2 | 44.6% | +83.5% |
| CHANDRA, GYAN | 1 | 71.1% | +27.7% |
| PETERS, ALEC JON | 1 | 68.6% | +61.7% |
| AEDER, SEAN E | 1 | 56.9% | +19.6% |
| BELYAVSKYI, MICHAIL A | 1 | 63.8% | +27.5% |
| KAUFMAN, CLAIRE M | 1 | 62.8% | +51.3% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.4% |
| NATARAJAN, MEERA | 1 | 62.2% | +16.8% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.3% |
| DAHLE, CHUN WU | 1 | 50.1% | +51.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17349482 | POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR | DAHLE, CHUN WU | 78d overdue |
| 17628382 | AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER | CHASE, CAROL ANN | 72d overdue |
| 17939736 | PRODUCTION OF HETERODIMERIC PROTEINS | HUYNH, PHUONG N | 24d overdue |
| 17972867 | MONOCLONAL ANTIBODIES AGAINST C-MET | KAUFMAN, CLAIRE M | 18d overdue |
| 17792268 | FORMULATIONS OF CD38 ANTIBODIES AND USES THEREOF | CHASE, CAROL ANN | 17d overdue |
| 18025208 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | AEDER, SEAN E | 16d overdue |
| 17957302 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | PUTTLITZ, KARL J | 5d overdue |
| 18478711 | ANTIBODIES BINDING TO CD30 AND CD3 | CHANDRA, GYAN | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1641 | 3 |
| 1646 | 3 |
| 1674 | 2 |
| 1644 | 2 |
| 1642 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18478711 | ANTIBODIES BINDING TO CD30 AND CD3 | CHANDRA, GYAN | 1674 | Other | Final Rejection | 4d overdue | Pending | Sep 29, 2023 |
| 18025202 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | PETERS, ALEC JON | 1641 | Other | Non-Final OA | 19d | Pending | Mar 08, 2023 |
| 18025208 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | AEDER, SEAN E | 1642 | §103 | Final Rejection | 16d overdue | Pending | Mar 08, 2023 |
| 18010783 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | BELYAVSKYI, MICHAIL A | 1644 | Other | Non-Final OA | 7d | Pending | Dec 15, 2022 |
| 17972867 | MONOCLONAL ANTIBODIES AGAINST C-MET | KAUFMAN, CLAIRE M | 1674 | §112 | Non-Final OA | 18d overdue | Pending | Oct 25, 2022 |
| 17957302 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | PUTTLITZ, KARL J | 1646 | Other | Non-Final OA | 5d overdue | Pending | Sep 30, 2022 |
| 17950350 | INERT FORMAT | NATARAJAN, MEERA | 1643 | Other | Non-Final OA | 33d | Pending | Sep 22, 2022 |
| 17939736 | PRODUCTION OF HETERODIMERIC PROTEINS | HUYNH, PHUONG N | 1641 | Other | Final Rejection | 24d overdue | Pending | Sep 07, 2022 |
| 17792268 | FORMULATIONS OF CD38 ANTIBODIES AND USES THEREOF | CHASE, CAROL ANN | 1646 | Other | Non-Final OA | 17d overdue | Pending | Jul 12, 2022 |
| 17628382 | AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER | CHASE, CAROL ANN | 1646 | Other | Non-Final OA | 72d overdue | Pending | Jan 19, 2022 |
| 17349482 | POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR | DAHLE, CHUN WU | 1641 | Other | Final Rejection | 78d overdue | Pending | Jun 16, 2021 |
| 16702996 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | SKELDING, ZACHARY S | 1644 | §112 | Final Rejection | 117d overdue | Pending | Dec 04, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial